Azitra, Inc. Announces FY 2024 Financial Results and Business Updates

BRANFORD, Conn., February 24, 2025 – Azitra, Inc. today released its financial results for the fiscal year ended December 31, 2024, while also providing key clinical and business updates. The clinical stage biopharmaceutical company, which focuses on developing innovative therapies in precision dermatology, detailed several milestones in its press release filed as part of its recent SEC Form 8-K.

The company’s lead product candidate, ATR-12, an engineered strain of Staphylococcus epidermidis aimed at treating Netherton syndrome, initiated a Phase 1b clinical trial in adult patients last August. Azitra expects initial safety data from these patients in the first half of 2025, with topline data anticipated by the end of the year.

In parallel, Azitra’s ATR-04 candidate – being developed for the treatment of moderate to severe EGFR inhibitor-associated dermal toxicity – received clearance from the U.S. Food and Drug Administration for its first-in-human Phase 1/2 clinical study. The trial, which is set to initiate in the first half of 2025, follows the FDA’s granting of Fast Track designation to ATR-04, signaling the agency’s recognition of the unmet need in treating EGFRi-associated skin rash.

Additional business highlights from the full year 2024 include the company’s successful closing of public offerings totaling $15 million and the strengthening of its intellectual property portfolio through newly granted and allowed patents.

On the financial front, Azitra reported a net loss of $9.0 million for the year, an improvement compared to the $11.3 million net loss recorded in fiscal 2023. Research and development expenses increased to $4.7 million from $3.6 million, while general and administrative expenses rose to $6.3 million from $4.5 million. As of December 31, 2024, the company reported cash and cash equivalents of approximately $4.6 million, excluding roughly $2.2 million in gross proceeds raised from follow-on offerings in January and February 2025.

Chief Executive Officer Francisco D. Salva emphasized the company’s strategic focus on utilizing its proprietary platform of engineered proteins to advance its therapeutic candidates. “We are positioning Azitra to address several dermatological conditions that are significantly underserved by current treatment options,” Salva stated. “Our clinical programs, underscored by meaningful milestones expected in 2025, offer potential inflection points that could drive shareholder value.”

Azitra, Inc. continues to advance its pipeline with ATR-12 and ATR-04 as central pillars of its growth strategy. The company’s ongoing investments in clinical research and intellectual property are expected to further its development efforts, with upcoming data readouts anticipated to bolster its strategic outlook in the precision dermatology space.

Investors and stakeholders are advised to review the full details released by the company in its SEC filing for additional financial information and forward-looking statements regarding its clinical and operational plans.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Azitra’s 8K filing here.

About Azitra

Azitra, Inc, an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease.